Chapter 1 Poxviridae Infections Drug Market Overview
1.1 Poxviridae Infections Drug Definition
1.2 Global Poxviridae Infections Drug Market Size Status and Outlook (2015-2030)
1.3 Global Poxviridae Infections Drug Market Size Comparison by Region (2015-2030)
1.4 Global Poxviridae Infections Drug Market Size Comparison by Type (2015-2030)
1.5 Global Poxviridae Infections Drug Market Size Comparison by Application (2015-2030)
1.6 Global Poxviridae Infections Drug Market Size Comparison by Sales Channel (2015-2030)
1.7 Poxviridae Infections Drug Market Dynamics (COVID-19 Impacts)
1.7.1 Market Drivers/Opportunities
1.7.2 Market Challenges/Risks
1.7.3 Market News (Mergers/Acquisitions/Expansion)
1.7.4 COVID-19 Impacts on Current Market
1.7.5 Post-Strategies of COVID-19 Outbreak
Chapter 2 Poxviridae Infections Drug Market Segment Analysis by Player
2.1 Global Poxviridae Infections Drug Sales and Market Share by Player (2018-2020)
2.2 Global Poxviridae Infections Drug Revenue and Market Share by Player (2018-2020)
2.3 Global Poxviridae Infections Drug Average Price by Player (2018-2020)
2.4 Players Competition Situation & Trends
2.5 Conclusion of Segment by Player
Chapter 3 Poxviridae Infections Drug Market Segment Analysis by Type
3.1 Global Poxviridae Infections Drug Market by Type
3.1.1 CJ-40011
3.1.2 24a
3.1.3 BA-368
3.1.4 Others
3.2 Global Poxviridae Infections Drug Sales and Market Share by Type (2015-2020)
3.3 Global Poxviridae Infections Drug Revenue and Market Share by Type (2015-2020)
3.4 Global Poxviridae Infections Drug Average Price by Type (2015-2020)
3.5 Leading Players of Poxviridae Infections Drug by Type in 2020
3.6 Conclusion of Segment by Type
Chapter 4 Poxviridae Infections Drug Market Segment Analysis by Application
4.1 Global Poxviridae Infections Drug Market by Application
4.1.1 Hospital Pharmacy
4.1.2 Retail Pharmacy
4.1.3 Others
4.2 Global Poxviridae Infections Drug Revenue and Market Share by Application (2015-2020)
4.3 Leading Consumers of Poxviridae Infections Drug by Application in 2020
4.4 Conclusion of Segment by Application
Chapter 5 Poxviridae Infections Drug Market Segment Analysis by Sales Channel
5.1 Global Poxviridae Infections Drug Market by Sales Channel
5.1.1 Direct Channel
5.1.2 Distribution Channel
5.2 Global Poxviridae Infections Drug Revenue and Market Share by Sales Channel (2015-2020)
5.3 Leading Distributors/Dealers of Poxviridae Infections Drug by Sales Channel in 2020
5.4 Conclusion of Segment by Sales Channel
Chapter 6 Poxviridae Infections Drug Market Segment Analysis by Region
6.1 Global Poxviridae Infections Drug Market Size and CAGR by Region (2015-2030)
6.2 Global Poxviridae Infections Drug Sales and Market Share by Region (2015-2020)
6.3 Global Poxviridae Infections Drug Revenue and Market Share by Region (2015-2020)
6.4 North America
6.4.1 North America Market by Country
6.4.2 North America Poxviridae Infections Drug Market Share by Type
6.4.3 North America Poxviridae Infections Drug Market Share by Application
6.4.4 United States
6.4.5 Canada
6.4.6 Mexico
6.5 Europe
6.5.1 Europe Market by Country
6.5.2 Europe Poxviridae Infections Drug Market Share by Type
6.5.3 Europe Poxviridae Infections Drug Market Share by Application
6.5.4 Germany
6.5.5 UK
6.5.6 France
6.5.7 Italy
6.5.8 Russia
6.5.9 Spain
6.6 Asia-Pacific
6.6.1 Asia-Pacific Market by Country
6.6.2 Asia-Pacific Poxviridae Infections Drug Market Share by Type
6.6.3 Asia-Pacific Poxviridae Infections Drug Market Share by Application
6.6.4 China
6.6.5 Japan
6.6.6 Korea
6.6.7 India
6.6.8 Southeast Asia
6.6.9 Australia
6.7 South America
6.7.1 South America Market by Country
6.7.2 South America Poxviridae Infections Drug Market Share by Type
6.7.3 South America Poxviridae Infections Drug Market Share by Application
6.7.4 Brazil
6.7.5 Argentina
6.7.6 Colombia
6.8 Middle East & Africa
6.8.1 Middle East & Africa Market by Country
6.8.2 Middle East & Africa Poxviridae Infections Drug Market Share by Type
6.8.3 Middle East & Africa Poxviridae Infections Drug Market Share by Application
6.8.4 UAE
6.8.5 Saudi Arabia
6.8.6 South Africa
6.9 Conclusion of Segment by Region
Chapter 7 Profile of Leading Poxviridae Infections Drug Players
7.1 Takeda Pharmaceutical
7.1.1 Company Snapshot
7.1.2 Product/Service Offered
7.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)
7.1.4 COVID-19 Impact on Takeda Pharmaceutical
7.2 China Biologic Products
7.3 CEL-SCI
7.4 Chimerix
7.5 Bavarian Nordic
7.6 Verrica Pharmaceuticals
7.7 CJ HealthCare
7.8 EpiVax
7.9 SIGA Technologies
7.10 N & N Pharmaceuticals
7.11 BioFactura
7.12 Tonix Pharmaceuticals
Chapter 8 Upstream and Downstream Analysis of Poxviridae Infections Drug
8.1 Industrial Chain of Poxviridae Infections Drug
8.2 Upstream of Poxviridae Infections Drug
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.2.4 Manufacturing Cost Structure
8.2.5 Manufacturing Process
8.3 Downstream of Poxviridae Infections Drug
8.3.1 Leading Distributors/Dealers of Poxviridae Infections Drug
8.3.2 Leading Consumers of Poxviridae Infections Drug
Chapter 9 Development Trend of Poxviridae Infections Drug (2021-2030)
9.1 Global Poxviridae Infections Drug Market Size (Sales and Revenue) Forecast (2021-2030)
9.2 Global Poxviridae Infections Drug Market Size and CAGR Forecast by Region (2021-2030)
9.3 Global Poxviridae Infections Drug Market Size and CAGR Forecast by Type (2021-2030)
9.4 Global Poxviridae Infections Drug Market Size and CAGR Forecast by Application (2021-2030)
9.5 Global Poxviridae Infections Drug Market Size and CAGR Forecast by Sales Channel (2021-2030)
Chapter 10 Appendix
10.1 Research Methodology
10.2 Data Sources
10.3 Disclaimer
10.4 Analysts Certification
